Current use and development of vaccines for Japanese encephalitis
- PMID: 18081539
- DOI: 10.1517/14712598.8.1.95
Current use and development of vaccines for Japanese encephalitis
Abstract
Background: Japanese encephalitis (JE) is a significant cause of human morbidity and mortality throughout Asia. Vaccines for JE have been available for many years and their use has been effective in reducing the incidence of JE disease in several countries but, as disease incidence has decreased, concerns regarding adverse events following immunisation have increased.
Objective: To review existing JE vaccines and new candidates in advanced preclinical or clinical evaluation.
Methods: The review primarily covers published and some unpublished literature from the past decade describing current use of approved JE vaccines in various parts of the world, and advanced development and clinical testing of alternative vaccine candidates.
Results/conclusion: There is a clear need for additional licensing of existing or new JE vaccines. Several promising candidates are currently in use or completing clinical trials.
Similar articles
-
Sero-Molecular Epidemiology of Japanese Encephalitis in Zhejiang, an Eastern Province of China.PLoS Negl Trop Dis. 2016 Aug 25;10(8):e0004936. doi: 10.1371/journal.pntd.0004936. eCollection 2016 Aug. PLoS Negl Trop Dis. 2016. PMID: 27560360 Free PMC article.
-
ChimeriVax-JE. Acambis.Curr Opin Investig Drugs. 2003 Aug;4(8):1019-22. Curr Opin Investig Drugs. 2003. PMID: 14508887 Review.
-
Japanese encephalitis vaccines: current vaccines and future prospects.Curr Top Microbiol Immunol. 2002;267:105-38. doi: 10.1007/978-3-642-59403-8_6. Curr Top Microbiol Immunol. 2002. PMID: 12082985 Review.
-
Low Protective Efficacy of the Current Japanese Encephalitis Vaccine against the Emerging Genotype 5 Japanese Encephalitis Virus.PLoS Negl Trop Dis. 2016 May 3;10(5):e0004686. doi: 10.1371/journal.pntd.0004686. eCollection 2016 May. PLoS Negl Trop Dis. 2016. PMID: 27139722 Free PMC article.
-
WHO working group on the quality, safety and efficacy of japanese encephalitis vaccines (live attenuated) for human use, Bangkok, Thailand, 21-23 February 2012.Biologicals. 2013 Nov;41(6):450-7. doi: 10.1016/j.biologicals.2013.06.001. Epub 2013 Jul 25. Biologicals. 2013. PMID: 23891495
Cited by
-
Japanese encephalitis in travelers from non-endemic countries, 1973-2008.Am J Trop Med Hyg. 2010 May;82(5):930-6. doi: 10.4269/ajtmh.2010.09-0676. Am J Trop Med Hyg. 2010. PMID: 20439978 Free PMC article.
-
Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India.BMC Infect Dis. 2014 Mar 21;14:156. doi: 10.1186/1471-2334-14-156. BMC Infect Dis. 2014. PMID: 24656175 Free PMC article. Clinical Trial.
-
Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.Hum Vaccin Immunother. 2017 Jun 3;13(6):1-18. doi: 10.1080/21645515.2017.1285472. Epub 2017 Feb 22. Hum Vaccin Immunother. 2017. PMID: 28301270 Free PMC article. Review.
-
An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses.J Gen Virol. 2010 Jun;91(Pt 6):1407-17. doi: 10.1099/vir.0.019190-0. Epub 2010 Feb 3. J Gen Virol. 2010. PMID: 20130134 Free PMC article.
-
Shift in dominant genotypes of Japanese encephalitis virus and its impact on current vaccination strategies.Front Microbiol. 2023 Nov 17;14:1302101. doi: 10.3389/fmicb.2023.1302101. eCollection 2023. Front Microbiol. 2023. PMID: 38045034 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous